Want to see AU:MVP full AI Analyst Report?
MVP Stock Chart & Stats
AU$0.50
-AU$0.02(-4.00%)
At close: 4:00 PM EDT
AU$0.50
-AU$0.02(-4.00%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$0.77
Previous CloseN/A
Volume529.07K
Average Volume (3M)118.82K
Market Cap
AU$53.51M
Enterprise ValueAU$26.09
Total Cash (Recent Filing)AU$21.37M
Total Debt (Recent Filing)AU$1.67M
Price to Earnings (P/E)84.8
Beta1.43
Next Earnings
Feb 25, 2027EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding112,658,325
10 Day Avg. Volume79,692
30 Day Avg. Volume118,816
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)0.80
Price to Sales (P/S)1.05
P/FCF Ratio8.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$46.80M
Bulls Say, Bears Say
Bulls Say
Penthrox Regulatory And Clinical ExpansionBroader pediatric eligibility, clinical evidence and documented emergency-department benefits can expand Penthrox adoption, strengthen its value proposition with healthcare providers and support durable penetration across European and Australian markets.
Improved Cash Generation And Conservative LeverageThe return to positive cash generation alongside minimal leverage gives MVP financial flexibility to fund registration, evidence generation and geographic expansion without relying heavily on external capital.
Strong Pain Management Growth Across MarketsGrowth in the core Pain Management franchise is broad-based rather than dependent on one geography, while rising hospital and international volumes create a durable pathway for Penthrox expansion beyond its established ambulance channel.
Bears Say
Thin And Historically Volatile ProfitabilityAlthough earnings recovered, margins remain thin and the history of substantial losses shows that profitability is not yet resilient. Small changes in demand, costs, foreign exchange or working capital could materially affect reported earnings.
Respiratory Segment WeaknessThe weaker Respiratory business reduces diversification and offsets part of the Pain Management recovery. Continued softness, especially in the U.S., could constrain consolidated growth and make results more dependent on successful Penthrox expansion.
FY2027 Earnings Headwinds And Limited Ambulance GrowthNear-term comparisons will be harder because FY2026 benefited from inventory and working-capital timing, while new amortisation reduces reported profit. Saturation in the foundational ambulance channel also raises the execution burden on hospitals and new markets.
Medical Developments International Limited News
MVP FAQ
What was Medical Developments International Limited’s price range in the past 12 months?
Medical Developments International Limited lowest share price was AU$0.36 and its highest was AU$0.77 in the past 12 months.
What is Medical Developments International Limited’s market cap?
Medical Developments International Limited’s market cap is AU$53.51M.
When is Medical Developments International Limited’s upcoming earnings report date?
Medical Developments International Limited’s upcoming earnings report date is Feb 25, 2027 which is in 186 days.
How were Medical Developments International Limited’s earnings last quarter?
Medical Developments International Limited released its earnings results on Aug 19, 2026. The company reported -AU$0.006 earnings per share for the quarter, the consensus estimate of -AU$0.006 by AU$0.
Is Medical Developments International Limited overvalued?
According to Wall Street analysts Medical Developments International Limited’s price is currently Undervalued.
Does Medical Developments International Limited pay dividends?
Medical Developments International Limited pays a Semiannually dividend of AU$0.019 which represents an annual dividend yield of N/A. See more information on Medical Developments International Limited dividends here
What is Medical Developments International Limited’s EPS estimate?
Medical Developments International Limited’s EPS estimate is 0.02.
How many shares outstanding does Medical Developments International Limited have?
Medical Developments International Limited has 112,658,325 shares outstanding.
What happened to Medical Developments International Limited’s price movement after its last earnings report?
Medical Developments International Limited reported an EPS of -AU$0.006 in its last earnings report, expectations of -AU$0.006. Following the earnings report the stock price went down -7.767%.
Which hedge fund is a major shareholder of Medical Developments International Limited?
Currently, no hedge funds are holding shares in AU:MVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medical Developments International Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (100.00% Upside)
AU$1.00 (100.00% Upside)
Blogger Sentiment
Bullish
AU:MVP Sentiment 100%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.70%
Trailing 12-Months
Company Description
Medical Developments International Limited
Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divided into two primary segments: Pain Management and Respiratory care. Among its key offerings is Penthrox, a product specifically formulated for rapid pain relief in acute trauma and emergency situations. Within the respiratory segment, MDIL supplies equipment designed to assist individuals with conditions like asthma and chronic obstructive pulmonary disease (COPD). Additionally, its comprehensive portfolio features a diverse array of medical devices, encompassing items such as CPR face shields and masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, oxygen resuscitation kits, and various oxygen therapy and resuscitation apparatus. Established in 2003, the company maintains its headquarters in Scoresby, Australia.
MVP Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(100.00% Upside)
Technical Analysis
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―